S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

$0.98
-0.02 (-2.00%)
(As of 03/1/2024 ET)
Today's Range
$0.98
$1.02
50-Day Range
$0.51
$1.06
52-Week Range
$0.47
$7.46
Volume
100,178 shs
Average Volume
175,416 shs
Market Capitalization
$29.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

DURECT MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,466.7% Upside
$35.00 Price Target
Short Interest
Healthy
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.72mentions of DURECT in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

129th out of 952 stocks

Pharmaceutical Preparations Industry

48th out of 436 stocks


DRRX stock logo

About DURECT Stock (NASDAQ:DRRX)

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock Price History

DRRX Stock News Headlines

DRRX Mar 2024 1.500 put
DURECT (NASDAQ:DRRX) Upgraded by StockNews.com to Hold
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
DURECT: Reading Into AHFIRM Mortality Rates
Recap: Durect Q3 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Durect Corp DRRX
4DRRX : Durect Earnings Preview
JonesTrading Downgrades Durect (DRRX)
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
3/02/2024
Next Earnings (Estimated)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRRX
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$41.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+3,466.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-398.65%
Pretax Margin
-398.65%

Debt

Sales & Book Value

Annual Sales
$9.19 million
Book Value
$1.10 per share

Miscellaneous

Free Float
28,546,000
Market Cap
$29.27 million
Optionable
Optionable
Beta
0.81

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. James E. Brown D.V.M. (Age 67)
    Co-Founder, CEO, President & Director
    Comp: $885.86k
  • Ms. Judy R. Joice (Age 67)
    Senior Vice President of Operations & Corporate Quality Assurance
    Comp: $451.82k
  • Dr. Norman L. Sussman M.D. (Age 71)
    Chief Medical Officer
    Comp: $587.95k
  • Mr. Timothy M. Papp M.B.A. (Age 48)
    CFO & Secretary
  • Ms. Jian Li M.B.A. (Age 54)
    Interim Principal Accounting Officer, Senior VP of Finance, Corporate Controller & Secretary
    Comp: $297.08k
  • Dr. WeiQi Lin M.D.
    Ph.D., Executive VP of Research & Development and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Senior Vice President of Business Development, Commercial & Medical Affairs
  • Dr. Su Il Yum Ph.D. (Age 85)
    Executive Officer
    Comp: $331.74k














DRRX Stock Analysis - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price target for 2024?

4 brokerages have issued 1 year price targets for DURECT's shares. Their DRRX share price targets range from $27.00 to $41.00. On average, they expect the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 3,466.7% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2024?

DURECT's stock was trading at $0.59 on January 1st, 2024. Since then, DRRX shares have increased by 66.3% and is now trading at $0.9813.
View the best growth stocks for 2024 here
.

Are investors shorting DURECT?

DURECT saw a decline in short interest in February. As of February 15th, there was short interest totaling 994,700 shares, a decline of 14.3% from the January 31st total of 1,160,000 shares. Based on an average daily trading volume, of 282,100 shares, the short-interest ratio is currently 3.5 days. Approximately 3.6% of the shares of the company are short sold.
View DURECT's Short Interest
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 289.99% and a negative net margin of 398.65%. During the same period last year, the firm earned ($0.50) earnings per share.

When did DURECT's stock split?

DURECT's stock reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

Who are DURECT's major shareholders?

DURECT's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.60%), Richmond Brothers Inc. (1.74%), Silverberg Bernstein Capital Management LLC (0.16%), Virtu Financial LLC (0.15%), Barclays PLC (0.00%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRRX) was last updated on 3/2/2024 by MarketBeat.com Staff